Search results
Results from the WOW.Com Content Network
In the trial, Jardiance cut the combined risk of cardiovascular death or hospitalization from heart failure in HFpEF patients with or without diabetes. At the 26-month mark, 13.8% of Jardiance ...
The main efficacy measurement was the time to death from cardiovascular causes or need to be hospitalized for heart failure. [33] Of the individuals who received empagliflozin for an average of about two years, 14% died from cardiovascular causes or were hospitalized for heart failure, compared to 17% of the participants who received the ...
In a statement on Friday, the two partners said Jardiance cut the risk of kidney disease progression and cardiovascular death by 28%, citing results from a late-stage trial which included people ...
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
Cardiologists are begging everyone to take an easy step to protect their heart health this fall and winter—but fewer than one in five people have actually done it. Related: ...
The pericardium (pl.: pericardia), also called pericardial sac, is a double-walled sac containing the heart and the roots of the great vessels. [1] It has two layers, an outer layer made of strong inelastic connective tissue (fibrous pericardium), and an inner layer made of serous membrane (serous pericardium).
“Estrogen is very protective of heart health for women. Pre-menopausal women, who have plentiful levels of estrogen, have a much lower risk for heart disease and high blood pressure than men.
Data from a new clinical trial suggest that people with obesity and cardiovascular disease who use semaglutide drugs, such as Ozempic and Wegovy, have a lower risk of adverse events related to ...